Clinical studies, especially randomized, controlled trials, are essential for generating
evidence for clinical practice. However, generalizability is a long‐standing concern when …

Introduction: Direct-acting antivirals (DAA) have revolutionized the modern treatment of
chronic hepatitis C (HCV). These highly efficacious, well-tolerated, all-oral HCV regimens …

The treatment of chronic hepatitis C (HCV) in human immunodeficiency virus 1 (HIV)–
infected individuals has been historically marked by low sustained virologic response (SVR) …

Background. Highly effective hepatitis C virus (HCV) therapies have spurred a scale-up of
treatment to populations at greater risk of reinfection after sustained virologic response …

Background. Large cohorts are needed to assess human immunodeficiency virus
(HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the effectiveness …

The advent of direct-acting antiviral (DAA) therapies has dramatically transformed HCV
treatment, with most recent trials demonstrating high efficacy rates (> 90%) across all …

We evaluated treatment outcomes in a prospective registry of human immunodeficiency
virus/hepatitis C virus (HCV)–coinfected patients treated with interferon‐free direct‐acting …

Abstract Purpose of Review Highly effective, well-tolerated interferon-free direct-acting
antivirals (DAA) have revolutionised hepatitis C virus (HCV) therapeutics, with the …

Abstract Background Direct-acting antivirals (DAAs) have revolutionized chronic hepatitis C
(HCV) treatment, but real-world effectiveness among vulnerable populations, including …

Background & Aims People who inject drugs (PWID) and are on opioid agonist therapy
(OAT) might have lower adherence to direct-acting antivirals (DAAs) against hepatitis C virus …